News Releases News Releases Year None20202019201820172016 Apr 02, 2020 SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS Mar 31, 2020 SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES Mar 25, 2020 Sorrento Launches Novel I-Cell™ COVID-19 Cellular Vaccine Program Mar 24, 2020 SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19 Mar 23, 2020 SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19 Mar 20, 2020 SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19) Mar 09, 2020 NK cells potential against Covid-19 Feb 27, 2020 Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial Feb 27, 2020 Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference Feb 21, 2020 Sorrento Therapeutics CEO Dr. Ji to Present at LEERINK Partners 9th Global Healthcare Conference Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Next page next › Last page last » Tools Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
News Releases Year None20202019201820172016 Apr 02, 2020 SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS Mar 31, 2020 SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES Mar 25, 2020 Sorrento Launches Novel I-Cell™ COVID-19 Cellular Vaccine Program Mar 24, 2020 SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19 Mar 23, 2020 SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19 Mar 20, 2020 SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19) Mar 09, 2020 NK cells potential against Covid-19 Feb 27, 2020 Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial Feb 27, 2020 Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference Feb 21, 2020 Sorrento Therapeutics CEO Dr. Ji to Present at LEERINK Partners 9th Global Healthcare Conference Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Next page next › Last page last »
Apr 02, 2020 SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS
Mar 31, 2020 SORRENTO AND THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON ENTER INTO PRECLINICAL TESTING AGREEMENT FOR COVID-19 THERAPEUTIC CANDIDATES
Mar 24, 2020 SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19
Mar 23, 2020 SORRENTO AND SMARTPHARM TO COLLABORATE TO DEVELOP NOVEL GENE-ENCODED ANTIBODY VACCINE INTENDED TO PROTECT AGAINST COVID-19
Mar 20, 2020 SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)
Feb 27, 2020 Sorrento Therapeutics Presents Interim Positive Results of Phase 1b Resiniferatoxin (RTX) in Cancer Pain Trial
Feb 27, 2020 Sorrento to Provide Corporate Update, Including DAR-T Cell Therapy Advances, at LEERINK Global Healthcare Conference
Feb 21, 2020 Sorrento Therapeutics CEO Dr. Ji to Present at LEERINK Partners 9th Global Healthcare Conference
